Basking Biosciences

Founded in 2019, Basking Biosciences is a clinical-stage company founded to solve the biggest need in ischemic stroke therapy for a rapid-onset, short-acting thrombolytic drug capable of reopening blocked arteries within a significantly extended therapeutic window than currently approved therapies, and whose activity can be quickly reversed in the... event of bleeding. The company is developing BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor (vWF), an important structural component of blood clots and driver of the clotting process. The company is also developing BB-025 in tandem, a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing BB-031 pharmacological activity. Non-clinical research in multiple gold-standard animal models demonstrated that BB-031 quickly recanalized blocked blood vessels in the brain, as late as six hours after stroke onset. Basking has successfully completed a Phase 1 single-ascending dose safety study with BB-031 and is initiating a Phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke with the ultimate goal of extending the therapeutic window for thrombolysis compared to currently approved therapies.Read More